These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease. Morenas-Rodríguez E; Alcolea D; Suárez-Calvet M; Muñoz-Llahuna L; Vilaplana E; Sala I; Subirana A; Querol-Vilaseca M; Carmona-Iragui M; Illán-Gala I; Ribosa-Nogué R; Blesa R; Haass C; Fortea J; Lleó A Sci Rep; 2019 May; 9(1):7803. PubMed ID: 31127154 [TBL] [Abstract][Full Text] [Related]
4. CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. Gispert JD; Monté GC; Falcon C; Tucholka A; Rojas S; Sánchez-Valle R; Antonell A; Lladó A; Rami L; Molinuevo JL Neurobiol Aging; 2016 Feb; 38():47-55. PubMed ID: 26827642 [TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease. Melah KE; Lu SY; Hoscheidt SM; Alexander AL; Adluru N; Destiche DJ; Carlsson CM; Zetterberg H; Blennow K; Okonkwo OC; Gleason CE; Dowling NM; Bratzke LC; Rowley HA; Sager MA; Asthana S; Johnson SC; Bendlin BB J Alzheimers Dis; 2016; 50(3):873-86. PubMed ID: 26836182 [TBL] [Abstract][Full Text] [Related]
6. Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer's disease. Hok-A-Hin YS; Del Campo M; Boiten WA; Stoops E; Vanhooren M; Lemstra AW; van der Flier WM; Teunissen CE J Neuroinflammation; 2023 May; 20(1):107. PubMed ID: 37147668 [TBL] [Abstract][Full Text] [Related]
8. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology. Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C; Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532 [TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal Fluid and Blood CX3CL1 as a Potential Biomarker in Early Diagnosis and Prognosis of Dementia. Kulczyńska-Przybik A; Słowik A; Mroczko P; Borawski B; Groblewska M; Borawska R; Mroczko B Curr Alzheimer Res; 2020; 17(8):709-721. PubMed ID: 33167838 [TBL] [Abstract][Full Text] [Related]
10. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease. Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298 [TBL] [Abstract][Full Text] [Related]
11. Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-β and tau pathology in Alzheimer's disease. Wang ZB; Ma YH; Sun Y; Tan L; Wang HF; Yu JT; J Neuroinflammation; 2022 Dec; 19(1):316. PubMed ID: 36578067 [TBL] [Abstract][Full Text] [Related]
12. Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis. Liu D; Cao B; Zhao Y; Huang H; McIntyre RS; Rosenblat JD; Zhou H Neurosci Lett; 2018 Nov; 686():10-16. PubMed ID: 30171911 [TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal Fluid sTREM2 in Alzheimer's Disease Is Associated with Both Amyloid and Tau Pathologies but not with Cognitive Status. Li TR; Lyu DY; Liu FQ; J Alzheimers Dis; 2022; 90(3):1123-1138. PubMed ID: 36213998 [TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup. Woollacott IOC; Nicholas JM; Heslegrave A; Heller C; Foiani MS; Dick KM; Russell LL; Paterson RW; Keshavan A; Fox NC; Warren JD; Schott JM; Zetterberg H; Rohrer JD Alzheimers Res Ther; 2018 Aug; 10(1):79. PubMed ID: 30111356 [TBL] [Abstract][Full Text] [Related]
16. Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: the CABLE study. Ma LZ; Tan L; Bi YL; Shen XN; Xu W; Ma YH; Li HQ; Dong Q; Yu JT Mol Neurodegener; 2020 Apr; 15(1):25. PubMed ID: 32276587 [TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype. Woollacott IOC; Nicholas JM; Heller C; Foiani MS; Moore KM; Russell LL; Paterson RW; Keshavan A; Schott JM; Warren JD; Heslegrave A; Zetterberg H; Rohrer JD Dement Geriatr Cogn Disord; 2020; 49(1):56-76. PubMed ID: 32344399 [TBL] [Abstract][Full Text] [Related]
18. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800 [TBL] [Abstract][Full Text] [Related]
19. Neuroimaging biomarkers and CSF sTREM2 levels in Alzheimer's disease: a longitudinal study. Nabizadeh F; Seyedmirzaei H; Karami S Sci Rep; 2024 Jul; 14(1):15318. PubMed ID: 38961148 [TBL] [Abstract][Full Text] [Related]
20. Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. Franzmeier N; Suárez-Calvet M; Frontzkowski L; Moore A; Hohman TJ; Morenas-Rodriguez E; Nuscher B; Shaw L; Trojanowski JQ; Dichgans M; Kleinberger G; Haass C; Ewers M; Mol Neurodegener; 2020 Oct; 15(1):57. PubMed ID: 33032659 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]